1092351-47-7 Usage
General Description
4-Amino-3-bromo-1-methylindazole is a specialized chemical compound with properties making it applicable in various research fields. Belonging to the indoazole family, this compound has the molecular formula C9H9BrN4 and is also known in chemical databases by its IUPAC name, 5-bromo-4-(1H-indazol-3-yl)aniline. As a derivative of indazole, it is characterized by a fused pyrazole and benzene ring, which is functionalized with a bromine and an amine group. While specific information about its properties or uses is limited, similar indazole derivatives have commonly been utilized in the development of pharmaceuticals, agricultural chemicals, dyes, and functional materials, indicating the potential applications for this compound.
Check Digit Verification of cas no
The CAS Registry Mumber 1092351-47-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,9,2,3,5 and 1 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1092351-47:
(9*1)+(8*0)+(7*9)+(6*2)+(5*3)+(4*5)+(3*1)+(2*4)+(1*7)=137
137 % 10 = 7
So 1092351-47-7 is a valid CAS Registry Number.
1092351-47-7Relevant articles and documents
Identification of pyrazolopyrimidine arylsulfonamides as CC-chemokine receptor 4 (CCR4) antagonists
Miah, Afjal H.,Champigny, Aurelie C.,Graves, Rebecca H.,Hodgson, Simon T.,Percy, Jonathan M.,Procopiou, Panayiotis A.
, p. 5327 - 5340 (2017/10/05)
A novel 4-aminoindazole sulfonamide hit (13) was identified as a human CCR4 antagonists from testing a focussed library of compounds in the primary GTPγS assay. Replacing the indazole core with a pyrazolopyrimidine, and introduction of a methoxy group adjacent to the sulfonamide substituent, resulted in the identification of pyrazolopyrimidine 37a, which exhibited good binding affinity in the GTPγS assay (pIC50 = 7.2), low lipophilicity (c log P = 2.2, chromlog D7.4 = 2.4), high LE (0.41), high solubility (CLND solubility ≥581 μM), and an excellent PK profile in both the rat (F = 62%) and the dog (F = 100%). Further SAR investigation of the pyrazolopyrimidine suggested that substitution at N1 is tolerated, providing a suitable vector to modulate the properties, and increase the potency in a lead optimisation campaign.
